ORIC® Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
ORIC Pharmaceuticals (Nasdaq: ORIC), a clinical stage oncology company specializing in treatments for therapeutic resistance, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's CEO, Jacob M. Chacko, M.D., will deliver a company overview presentation on Tuesday, January 14, 2025, at 11:15 a.m. PT.
The presentation will be accessible via live webcast through the investor section of ORIC's website at www.oricpharma.com. Interested parties who cannot attend the live presentation will have access to a replay of the webcast, which will remain available for 90 days after the event.
ORIC Pharmaceuticals (Nasdaq: ORIC), un'azienda oncologica in fase clinica specializzata nel trattamento della resistenza terapeutica, ha annunciato la sua partecipazione al 43° J.P. Morgan Healthcare Conference. Il CEO dell'azienda, Jacob M. Chacko, M.D., presenterà una panoramica dell'azienda il martedì 14 gennaio 2025, alle 11:15 PT.
La presentazione sarà accessibile tramite webcast in diretta nella sezione investitori del sito web di ORIC all'indirizzo www.oricpharma.com. Le parti interessate che non possono partecipare alla presentazione dal vivo potranno accedere a una registrazione del webcast, che rimarrà disponibile per 90 giorni dopo l'evento.
ORIC Pharmaceuticals (Nasdaq: ORIC), una empresa de oncología en etapa clínica que se especializa en tratamientos para la resistencia terapéutica, ha anunciado su participación en la 43ª Conferencia Anual de Atención Médica de J.P. Morgan. El CEO de la empresa, Jacob M. Chacko, M.D., realizará una presentación sobre la empresa el martes 14 de enero de 2025, a las 11:15 a. m. PT.
La presentación será accesible a través de una transmisión web en vivo a través de la sección para inversores del sitio web de ORIC en www.oricpharma.com. Las partes interesadas que no puedan asistir a la presentación en vivo tendrán acceso a una reproducción de la transmisión, que estará disponible durante 90 días después del evento.
ORIC Pharmaceuticals (Nasdaq: ORIC), 치료 저항성 치료에 특화된 임상 단계의 종양학 회사가 제43회 J.P. 모건 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사의 CEO인 Jacob M. Chacko, M.D.는 2025년 1월 14일 화요일 오전 11시 15분 PT에 회사 개요 발표를 할 예정입니다.
발표는 ORIC 웹사이트의 투자자 섹션에서 실시간 웹캐스트를 통해 접근 가능합니다. 실시간 발표에 참석할 수 없는 이해 관계자들은 이벤트 후 90일 동안 이용 가능한 웹캐스트 재생에 접근할 수 있습니다.
ORIC Pharmaceuticals (Nasdaq: ORIC), une société d'oncologie en phase clinique spécialisée dans le traitement de la résistance thérapeutique, a annoncé sa participation à la 43e Conférence Annuelle de J.P. Morgan sur les Soins de Santé. Le PDG de l'entreprise, Jacob M. Chacko, M.D., présentera un aperçu de l'entreprise le mardi 14 janvier 2025, à 11h15 PT.
La présentation sera accessible par le biais d'un webcast en direct sur la section investisseurs du site web d'ORIC à l'adresse www.oricpharma.com. Les parties intéressées qui ne peuvent pas assister à la présentation en direct auront accès à une rediffusion du webcast, qui sera disponible pendant 90 jours après l'événement.
ORIC Pharmaceuticals (Nasdaq: ORIC), ein Unternehmen in der klinischen Phase mit Spezialisierung auf Behandlungen bei therapeutischer Resilienz, hat seine Teilnahme an der 43. J.P. Morgan Healthcare Conference bekannt gegeben. Der CEO des Unternehmens, Jacob M. Chacko, M.D., wird am Dienstag, den 14. Januar 2025, um 11:15 Uhr PT eine Unternehmensübersicht präsentieren.
Die Präsentation wird über einen Live-Stream im Investorenbereich der ORIC-Website unter www.oricpharma.com zugänglich sein. Interessierte Parteien, die nicht an der Live-Präsentation teilnehmen können, haben Zugang zu einer Wiederholung des Live-Streams, der für 90 Tage nach der Veranstaltung verfügbar bleibt.
- None.
- None.
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob M. Chacko, M.D., chief executive officer, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 11:15 a.m. PT.
A live webcast of the company presentation will be available through the investor section of the company’s website at www.oricpharma.com. A replay of the webcast will be available for 90 days following the event.
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers, and (2) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer. Beyond these two product candidates, ORIC® is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.
Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com
FAQ
When is ORIC Pharmaceuticals presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch ORIC's presentation at the J.P. Morgan Healthcare Conference?
How long will ORIC's J.P. Morgan Healthcare Conference presentation replay be available?
What is ORIC Pharmaceuticals' primary focus as a clinical stage oncology company?
